natural alternatives to glp-1 weight-loss drugs Top 5 You Might Consider Comparing GLP‑1 Drugs With Other

National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)

(WROC) Excellus BlueCross BlueShield is pushing back against reports that it will no longer cover GLP-1 medications, saying drugs used to treat certain medical conditions remain cove...

Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus

Increasingly, reports suggest a possible association between GLP-1 RA use and enhanced fertility outcomes, particularly in women with obesity or polycystic ovary syndrome (PCOS)

Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)

Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs